anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides substantially purified mammalian brevican, which is a chondroitin sulphate proteoglycan produced by glial cells. The invention provides, for example, the full-length 145 kDa form brevican as well as an 80 kDa active fragment of bovine brevican and of rat brevican. The invention also provides antibodies that are specific for a mammalian brevican and a cell line that produces a monoclonal antibrevican antibody. The invention further provides nucleic acid molecules encoding a mammalian brevican, vectors containing the nucleic acid molecules, host cells containing the vectors. The invention also provides nucleotide sequences that hybridize to a nucleic acid molecule encoding brevican. The invention also provides methods for detecting the presence of a glial cell in a cell sample suspected of containing a glial cell. The invention further provides methods for detecting a glial cell in a subject and methods for directing axonal growth or inhibiting axonal growth in a subject.
The invention disclosed a Huahong composition for treating gynopathy, and the composition is prepared by Emilia sonchifolia(L.) DC., Oldenlandia diffusa(Willd.)Rosb., Urena lobata L., Mallotus apelta(Lour.) Muell., Thlaspi arvense L., Spatholobus suberectus Dunn, and Rhodomyrtus tomentosa(Ait.) Hassk.. The invention raises the content of Sophretin, a active component of the composition by controlling temperature of drying to the range of 60-80°C. Sophretin is present in the composition of 0.06-0.11% by weight, and it is 2-3 times as compared with that of prior art.
Nowadays, the importance of exercise is highly valued. The prevalence of sports injury is also increasing and may be associated with muscle fatigue. Therefore, the study focused on the prevention of common muscle fatigue in legs during exercise. With the modern sport medicine knowledge and kinesio taping, the investigators tried to figure out whether muscle fatigue can be diminished through the concept of Chinese medicine channel sinews techniques in advance. In this study, 45 healthy participants between 20 and 40 of age will be included. The exclusion criteria are as follows: i.pregnancy ii.current health problem iii.injuries of legs within a month. After obtaining the consent, the participants will be categorized into two(A\&B) groups randomly for cross-over study. Each of group will accept either conventional taping or Chinese medicine technique taping before muscle fatigue exercise. To compare the preventive effect, Myoton PRO, pulse analysis equipment, etc will be applied for evaluation. The application of Chinese medicine technique (ie. Chinese medicine functional reduction) taking the kinetic chain into consideration may improve body's functional movement. Our goal is to enhance the coordination of the entire body structure, not merely the partial body structure improvement. In this way, it will benefit the prevention of exercise injuries and therapeutic effect.
The invention provides methods for modulating an immune response comprising contacting an immune cell with an agent that modulates BTF4 or B7-L1 mediated signaling. BTF4 or B7-L1 mediated signaling may either be increased, to thereby downregulate the immune response, or alternatively may be decreased, to upregulate the immune response. Modulation may be either activation or inhibition, and contacting may occur in vivo or in vitro. Performance of this method in vivo is also potentially therapeutic for an individual who may benefit from the upregulation or downregulation of an immune response. Such modulation to downregulate the immune response serves as a therapeutic e.g., for an individual who has received an organ transplant, or has a condition such as an allergy, or an autoimmune disorder. Alternatively, modulation to upregulate the immune response serves as a therapeutic for an individual, e.g., who has a condition such as an immunosuppressive disorder or a tumor.  Methods for identifying an agent that modulates BTF4 signaling or B7-Ll signaling is also provided.
This is a randomized, double-blind, active-controlled, flexible dosage, multicenter study to evaluate the effectiveness and safety of galantamine tablet in the treatment of mild to moderate AD. The comparator is Donepezil tablet. At least 206 patients were to be randomized in the study. The study consisted of 3 phases: a screening phase, a single-blind run-in phase and a double-blind treatment phase. Screening phase is less than 2 week for eligible assessment; If the patient was taking any anti-dementia drug at screening, he/she had to stop these drugs and enter into the single-blind run-in phase. The patient who did not take any anti-dementia drug can enter into baseline directly. During the single-blind run-in phase, all eligible patients will take placebo twice daily for 4 weeks. Double-blind treatment phase is 16 weeks. At baseline, all patients who are still eligible for inclusion/exclusion criteria will be randomized to either galantamine group or donepezil group at 1:1 ratio, drugs will be taken twice daily by a flexible dose for 16 weeks. Dose will be titrated during the first 9-12 weeks. Dose will be fixed to 16mg/day or 24mg/day based on tolerability of the patient judged by the investigator. The primary effectiveness endpoint is changes in ADAS-cog/11 at week 16 from baseline, secondary endpoint is responder rate in term of ADAS-cog/11. Safety evaluation included adverse events, physical examination, ECG, and safety laboratory tests. Study drug are taken orally twice a day. The treatment duration was 16 weeks. Initial galantamine dose is 8 mg/day, dose was increased to 16mg/day at week 5 and to 24 mg/day at week 9. At week 12, dose was fixed to either 16mg/day or 24mg/day at the discretion of investigators. Initial donepezil dose is 5mg/day, dose was then increased to 10mg/day at week 9. At week 12, dose was fixed to either 5mg/day or 10mg/day at the discretion of investigators.
The invention discloses application of palmatine oxide in preparation of a medicine for treating and/or preventing ulcerative colitis. Belongs to the technical field of biological medicine. The research of the invention finds that the palmatine oxide can safely and effectively resist ulcerative colitis, and comprises the steps of improving disease activity index of an ulcerative colitis individual, recovering colon length, relieving tissue pathological structure damage, improving the content of inflammatory factors of colon tissues, improving the content of oxidative stress related enzymes in the colon tissues, and regulating and controlling the expression levels of NLRP3 inflammasome and Nrf2 signal pathway related protein and mRNA. The effect of the palmatine oxide for preventing and treating ulcerative colitis is equivalent to that of the traditional first-line treatment medicament mesalazine, and is superior to that of palmatine. Has good application prospect for clinical treatment of ulcerative colitis. Moreover, the mouse acute toxicity test proves that the safety of the palmatine oxide is higher than that of the palmatine.
Patients with progressive mild and moderate grades of ketatoconus are randomized and allocated to this group and submitted to the treatment with riboflavin and ultraviolet -A light. They do not match any of the exclusion criterion: pregnancy, corneal thickness less than 400 μm, history of corneal surgery, herpes ocular infection, other corneal disease or scarring, chemical injuries and riboflavin allergy.
Individuals will receive 15sessions of the traditional form of basic locomotor training for 3 weeks. Repetitive stepping patterns are practiced on the treadmill and overground.
OBJECTIVE: This study aimed to identify which lumbar vertebral level above a lumbosacral transitional vertebra (LSTV) demonstrated the longest transverse process (TVP) lengths.
METHODS: In this exploratory quantitative osteological cohort study using a digital Vernier caliper, dried human cadaveric lumbar TVPs were measured for linear horizontal length at each lumbar vertebra, left and right sides. Data collection was conducted in South Africa at the Raymond A. Dart Collection of Modern Human Skeletons and the Pretoria Bone Collection. The LSTV cohort consisted of 110 spinal columns and an LSTV-free control cohort of a sex-balanced randomized selection of 30 male and 30 female spinal columns.
RESULTS: Compared with the control cohort, the LSTV cohort demonstrated longer TVPs for every vertebral level, particularly L3, while the left side demonstrated longer TVPs overall. There were no statistical differences in TVP length within the LSTV cohort when comparing all levels (P > 0.05). The L3 TVPs demonstrated the longest mean lengths in both control (65%) and LSTV (58%) cohorts. The general trend was that the TVPs of L3 had the longest mean length for both the left and the right sides in both cohorts and both sexes.
CONCLUSIONS: In the absence of whole-spine imaging, these findings indicate that L3 TVPs may offer an alternative bony landmark, which may aid in spinal enumeration estimation in the setting of LSTV. This is of value for radiograph appraisal and may aid with correct-level intervention.
The invention relates to a gene for expressing camel lactoferrin antibacterial peptide, antibacterial peptide and application thereof. The nucleotide sequence of the gene for expressing the camel lactoferrin antibacterial peptide is shown as SEQ ID NO. 1. The amino acid sequence of the antibacterial peptide is shown as SEQ ID NO. 2. Compared with the prior art, the invention screens the lactoferrin sequence in the camel body through NCBI database for the first time, predicts the conserved region in the lactoferrin sequence to obtain the nucleotide sequence, obtains the antibacterial peptide with antibacterial activity through genetic engineering, and has obvious antibacterial function, can effectively replace antibiotics and solve the problem of drug resistance, and the experiment proves that the antibacterial peptide can effectively inhibit the activity of staphylococcus aureus and escherichia coli.
Peripheral artery disease (PAD) is a progressive disease that occurs as the result of atherosclerotic plaque formation in the major arteries of the leg (Mays, Casserly and Regesteiner, 2013). The main presenting symptom of PAD is intermittent claudication (IC) - exertional pain or discomfort in the calf, thigh or buttock that is relieved with rest. The presence of PAD is a very powerful marker of cardiovascular risk and preventable cardiovascular deaths. Following the initial diagnosis of PAD, for those patients without coronary artery disease the risk of systemic morbidity or mortality in the next 5 years is 50% (AACVPR, 2013). In 2012, the National Institute for Health and Care Excellence (NICE) issued guidelines stating that supervised exercise programmes (SEPs) should be offered as first-line treatment for people diagnosed PAD. However, there is a national shortage of dedicated SEPs for PAD patients that UK vascular specialists can refer patients to. There has been suggestion that an already established network of Cardiac Rehabilitation (CR) departments within the United Kingdom (UK) could cater for this group of patients, as they already have facilities and staff in place. To date, there has been no investigation into whether this would be successful. This research project would investigate if CR programmes could get the same outcomes for PAD patients as a stand-alone PAD rehabilitation programme. The study would investigate the possible positive and negative impact on both the PAD and CR patient groups in attending a combined rehabilitation programme of exercise and education. It will also look at the perceptions of the participants regarding the treatment programme itself.
The duration of treatment for which a physician may prescribe a medicine, 'prescription duration', is often dispensed at the pharmacy on multiple occasions of shorter time periods, 'dispensing duration'. These durations vary significantly between and within countries. In Australia, the quantity of medication supplied at each dispensing has recently been extended from 30 to 60 days for a selection of medicines used for chronic health conditions, such as diabetes and hypertension. Dispensing durations vary between countries, with 30, 60 or 90 days being the most common-with 90 days aligning with the recommendation of the 2023 Global Report on Hypertension from the World Health Organization. The full impact of shorter vs longer prescription durations on health costs and outcomes is unknown, but current evidence suggests that 90-day dispensing could reduce costs and improve patient convenience and adherence. More rigorous research is needed.
This was a randomized, double-blind, study that was conducted in six health care centers from Medellín and Bogotá (Colombia). This study was conducted in compliance with the ethical principles of the Declaration of Helsinki and with Good Clinical Practice guidelines. Written informed consent was obtained from all subjects or they parents in patients under 18 years. Ethical committee of University of Antioquia (Medellín, Colombia) approved the protocol. Considering the large number of articles that demonstrate the efficacy of antihistamines as first-line treatment in patients with urticaria, the ethics committee request that all participants would receive an antihistamine during the two months of the study because a placebo group would provide little information for the principal objective and the high risk of airway angioedema. Thirty heath subjects were used as a control group to evaluated the characteristics of the wheal in the prick test with histamine.
The invention discloses a Chinese medicinal lotion for curing pet dermatomycosis and a preparation method of the lotion. The Chinese medicinal lotion of the invention comprises the following Chinese medicinal materials: 3-7g of Cnidium monnieri fruit, 3-7g of Kochia scoparia fruit, 1-4g of Radix Stemonae, 1-4g of Sanguisorba officinalis, 2-5g of Melia toosendan fruit and 2-5g of Polygonum aviculare. The preparation method of the lotion comprises crushing, ethanol-extracting, water-extracting and concentrating. The clinical practice indicates that the formula of the invention has a special efficiency to pet bacterial skin disease and dermatomycosis, especially to whole body large area infection which can be cured by 1-2 treatment courses without relapses. In addition, the formula of the invention has no toxic or side effects, no drug resistance generation, and is convenient to use, low in price and simple in preparation method. The drug of the invention provides a feasible way for industrialized large-scale production and is suitable to be popularized.
The participants in the Group C or control group will perform the PNF D2 flexion and extension without any resistance. Three sets consist of 10 repetitions of each pattern for both upper limbs will be performed with an interval of 60 seconds between two consecutive sets.
Subjects are persons with tetraplegia who completed Visit 1 (no drug). Subjects are administered a 10 mg tablet of midodrine hydrochloride by a physician before being exposed to cool temperature (64° F) for up to 2 hours in a temperature-controlled room in order to assess the body's temperature-regulating mechanisms and any associated change in cognitive performance (Visit 2).
The methods and compositions of the invention and the compounds used in the invention involve a novel immunosuppression mechanism, accelerated lymphocyte homing immunosuppression (ALH-immunosuppression). For example, the compound FTY720 specifically directs lymphocytes to the peripheral lymph nodes, mesenteric lymph nodes, and Peyer's patches. By reversibly sequestering lymphocytes in these tissues, the compounds can inhibit an immune response in a mammal. Understanding these mechanisms provides a novel immunosuppression therapy that can synergistically interact with other immunosuppressive compounds. Screening methods for identifying similar ALH-immunosuppression compounds are also described. The invention allows better treatments and therapies wherever an immunosuppression regimen is desired.
Background and Objectives: Sepsis represents a global health challenge and requires advanced diagnostic and prognostic approaches due to its elevated rate of morbidity and fatality. Our study aimed to assess the value of a novel set of six biomarkers combined with severity scores in predicting 28 day mortality among patients presenting with sepsis in the Emergency Department (ED). Materials and Methods: This single-center, observational, prospective cohort included sixty-seven consecutive patients with septic shock and sepsis enrolled from November 2020 to December 2022, categorized into survival and non-survival groups based on outcomes. The following were assessed: procalcitonin (PCT), soluble Triggering Receptor Expressed on Myeloid Cells-1 (sTREM-1), the soluble form of the urokinase plasminogen activator receptor (suPAR), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and azurocidin 1 (AZU1), alongside clinical scores such as the Quick Sequential Organ Failure Assessment (qSOFA), Systemic Inflammatory Response Syndrome (SIRS), the Sequential Organ Failure Assessment (SOFA), the Acute Physiology and Chronic Health Evaluation II (APACHE II), the Simplified Acute Physiology Score II and III (SAPS II/III), the National Early Warning Score (NEWS), Mortality in Emergency Department Sepsis (MEDS), the Charlson Comorbidity Index (CCI), and the Glasgow Coma Scale (GCS). The ability of each biomarker and clinical score and their combinations to predict 28 day mortality were evaluated. Results: The overall mortality was 49.25%. Mechanical ventilation was associated with a higher mortality rate. The levels of IL-6 were significantly higher in the non-survival group and had higher AUC values compared to the other biomarkers. The GCS, SOFA, APACHEII, and SAPS II/III showed superior predictive ability. Combining IL-6 with suPAR, AZU1, and clinical scores SOFA, APACHE II, and SAPS II enhanced prediction accuracy compared with individual biomarkers. Conclusion: In our study, IL-6 and SAPS II/III were the most accurate predictors of 28 day mortality for sepsis patients in the ED.
OBJECTIVE: The aims of this study were to assess first-year predoctoral dental students' knowledge, training, perceptions, and attitudes on obesity and to compare knowledge, perceptions, and attitudes before and after attending an educational presentation.
METHODS: A presentation explaining the impact of obesity and its treatments on oral health was developed and presented to first-year predoctoral dental students (D1's) in the Doctor of Dental Medicine program. Before ("pre") and after ("post") the presentation, attending students were given the opportunity to take an anonymous and voluntary survey. Questions on the survey covered topics on knowledge, training, perceptions, and attitudes about obesity.
RESULTS: Thirty-four of the 213 students in the course (response rate = 16.0%) attended the presentation and completed both the pre- and post-surveys. Most participating students reported receiving 0-5 h of education on obesity since starting their dental education. Regarding pre-survey answers to knowledge-based items, the percentage of students answering, "strongly agree" (representing the greatest knowledge level) ranged from 5.9% to 61.8% across items. Significant improvements from pre- to post-survey were observed for all knowledge-based items except a statement that obesity is associated with serious medical conditions. Significant improvements were also found for perception-based items asking about accommodations for patients and the importance of assessing dietary habits. Additionally, at post-survey, students reported significantly less discomfort asking about dietary habits and weight loss medications.
CONCLUSION: Dental curricula policy makers and developers should consider the incorporation of obesity and its treatments, with nutrition experts teaching the content.
This randomized controlled study is a two armed study, which will take place at two locations in Nepal. Eligible women will be invited to the study when attending routine antenatal care. Women agreeing to participate will be invited to first complete a questionnaire. Upon completion of this first questionnaire women will view either the intervention or control video, irrespective of their Domestic Violence (DV) Status. In the intervention arm all women will be shown the intervention video, irrespective of their DV status. In the control arm women view an intervention video. All women are asked to return to the study during the last two months of their pregnancy. All women will be asked to complete the second questionnaire. Upon completions all women will be offered to see the intervention video. For the intervention group this will be their second viewing, for the control group this will be the first viewing of the intervention video. All women will be followed up til birth. Data about their birth will be collected from their hospital records.
PURPOSE:To obtain a carrier which can be preserved for a long period of time by adjusting a soln. contg. gelatin, water soluble polysaccharides, sodium polymetaphosphate, as well as a hydrophilic org. solvent and water in a specific pH range by adding acids thereto to form particles then cooling the same to temp. lower than specific temp. and effecting crosslinking agents therewith. CONSTITUTION:Acids (acetic acid, etc.) are added to a soln. contg. gelatin, water soluble polysaccharides (gum arabic, etc.), sodium polymetaphosphate, and a hydrophilic org. solvent (alcohol, etc.) and water under stirring at temp. higher than the gelling temp. of the gelatin to adjust 2.5-6.0pH and to form a dispersion of gel particles. After the formation of the particles, the soln. is cooled and when the temp. thereof drops to <=10 deg.C, crosslinking agents (glutaraldehyde, CH3CHO, etc.) are added thereto to obtain crosslinked particles. The crosslinked particles are centrifugally separated and washed, whereby the carrier to be deposited thereon with antigens, etc. for serodiagnosis, etc. is obtained. This carrier is obtained in optional grain sizes according to production conditions, is good in yield, permits preservation for a long period of time and is usable anytime without liberation of antigens, etc. even when the carrier is bound with the antigens, etc. and is frozen and preserved.
Many types of tumors feature aerobic glycolysis for meeting their increased energetic and biosynthetic demands. However, it remains still unclear how this glycolytic phenomenon is achieved and coordinated with other metabolic pathways in tumor cells in response to growth stimuli. Here we report that activation of AKT1 induces a metabolic switch to glycolysis from the mitochondrial metabolism via phosphorylation of cytoplasmic malic enzyme 2 (ME2), named ME2fl (fl means full length), favoring an enhanced glycolytic phenotype. Mechanistically, in the cytoplasm, AKT1 phosphorylates ME2fl at serine 9 in the mitochondrial localization signal peptide at the N-terminus, preventing its mitochondrial translocation. Unlike mitochondrial ME2, which accounts for adjusting the tricarboxylic acid (TCA) cycle, ME2fl functions as a scaffold that brings together the key glycolytic enzymes phosphofructokinase (PFKL), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and pyruvate kinase M2 (PKM2), as well as Lactate dehydrogenase A (LDHA), to promote glycolysis in the cytosol. Thus, through phosphorylation of ME2fl, AKT1 enhances the glycolytic capacity of tumor cells in vitro and in vivo, revealing an unexpected role for subcellular translocation switching of ME2 mediated by AKT1 in the metabolic adaptation of tumor cells to growth stimuli.